secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001171843-23-006668
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q3 net loss $38.3M ($0.81/shr); Phase 2 CSU enrollment complete, data by YE 2023
--------------------------------------------------------------------------------

- Net loss of $38.3M ($0.81 per share) vs $26.8M ($0.57) a year ago; revenue $1.5M.
- Cash, equivalents and marketable securities $235.3M, sufficient to fund operations through 2025.
- Phase 2 CSU study (n=208) enrollment complete; topline data expected by end of 2023.
- Phase 1b prurigo nodularis data accepted for oral presentation at World Congress on Itch (Nov 5-7).
- Phase 2 studies in CIndU, EoE ongoing; Phase 2 PN study planned for early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184323006668/0001171843-23-006668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184323006668/f8k_110223.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer